Search

Your search keyword '"United Kingdom"' showing total 1 results

Refine your results

1 results on '"United Kingdom"'

1. PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM.

Author

García San Andrés, B., Ubi, S., Alvarez-Alvarez, R., Barwood, C., Olmedo-García, M.E., and Foster, M.

Subjects
*SMALL cell lung cancer, *TOPOTECAN, *ADVERSE health care events, *COST effectiveness, *GRANULOCYTE-colony stimulating factor
Abstract

To conduct an economic analysis comparing the costs of managing adverse events (AEs) and treatment administration in patients with relapsed small cell lung cancer (SCLC) treated either with lurbinectedin or intravenous (IV) topotecan. Lurbinectedin demonstrated consistent cost savings in terms of both treatment administration and management of AEs in Spain and the UK. [Extracted from the article]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results